About Us
About Us
Leadership
Experienced Leadership, United by Shared Mission
Our leadership team brings a proven track record of advancing first-in-class medicines from scientific discovery through clinical development, regulatory approval and commercialization. United by a shared mission, we are committed to translating differentiated science into transformative medicines for patients.
Kathy Dong, PharmD, MBA
President,
Chief Executive Officer and Director
Kim-Hien Dao, DO, PhD
Chief Medical Officer
Graham Parry, PhD
Chief Scientific Officer
Gary S. Koe, PhD
Chief Technical Officer
Chris Clark, CFA
Chief Financial Officer
Board of Directors
Nancy Stagliano, PhD
Executive Chair
Kathy Dong, PharmD, MBA
President,
Chief Executive Officer and Director
Beth Seidenberg, MD
Director
Carl Gordon, PhD, CFA
Director
Thomas Geninatti, PhD
Director
Matthew Fust, MBA
Director
Kathy Dong PharmD, MBA
President, Chief Executive Officer and Director
Kathy has served as President and Chief Executive Officer of Electra Therapeutics and a member of our board of directors since October 2023. She brings broad experience in corporate development, portfolio management, development operations, and product commercialization.
From April 2019 to October 2023, Kathy served as Chief Operating Officer of Star Therapeutics, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage through clinical development. Prior to Star Therapeutics, Kathy served as Vice President of Commercial Development at True North Therapeutics, where she played a key role in assessing opportunities and shaping the value proposition for its portfolio. Following True North’s acquisition by Bioverativ (which was subsequently acquired by Sanofi), she advanced numerous programs through preclinical and clinical development as Head of New Product Planning for the complement franchise at Sanofi, through March 2019. Earlier in her career, Kathy held leadership roles at Gilead Sciences, where she led the launch and market development of numerous products in Hepatitis B and Hepatitis C, including the successful launches of SOVALDI and HARVONI.
She has also served as an independent director on the board of Neuron23 since June 2022. Kathy earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.
Kathy Dong PharmD, MBA
President, Chief Executive Officer and Director
Kathy has served as President and Chief Executive Officer of Electra Therapeutics and a member of our board of directors since October 2023. She brings broad experience in corporate development, portfolio management, development operations, and product commercialization.
From April 2019 to October 2023, Kathy served as Chief Operating Officer of Star Therapeutics, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage through clinical development. Prior to Star Therapeutics, Kathy served as Vice President of Commercial Development at True North Therapeutics, where she played a key role in assessing opportunities and shaping the value proposition for its portfolio. Following True North’s acquisition by Bioverativ (which was subsequently acquired by Sanofi), she advanced numerous programs through preclinical and clinical development as Head of New Product Planning for the complement franchise at Sanofi, through March 2019. Earlier in her career, Kathy held leadership roles at Gilead Sciences, where she led the launch and market development of numerous products in Hepatitis B and Hepatitis C, including the successful launches of SOVALDI and HARVONI.
She has also served as an independent director on the board of Neuron23 since June 2022. Kathy earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.
X
Graham Parry PhD
Chief Scientific Officer
Graham has served as Chief Scientific Officer of Electra Therapeutics since December 2023. In this role, he works cross-functionally with scientists, clinicians, and the broader team at Electra to interrogate novel biology and advance our programs from discovery through the clinic.
Graham brings over 20 years of experience to the development of novel therapies for diseases with critical unmet needs. Prior to joining Electra, he served as Executive Vice President, Translational Sciences, at Star Therapeutics from January 2023 to December 2023, where he worked across the portfolio to advance treatments for multiple diseases. Prior to Star Therapeutics, he served as Senior Vice President, Translational Sciences at Third Harmonic Bio from August 2019 to December 2022, focused on treatments for allergic and inflammatory diseases, and as Vice President of Technical Operations at True North Therapeutics where he worked on the discovery and development of ENJAYMO®, a first-in-class inhibitor of the classical complement pathway approved for the treatment of cold agglutinin disease. Earlier in his career, he worked in drug development roles at iPierian in neurodegenerative diseases and Attenuon in cancer therapeutics, and as assistant professor at The Scripps Research Institute.
Graham earned his Ph.D. in Biochemistry at the University of London and his B.Sc. in Applied Biology at Brunel University of London.
X
Kim-Hien Dao DO, PhD
Chief Medical Officer
Kim-Hien has served as Chief Medical Officer of Electra Therapeutics since May 2024, and previously served as Vice President, Head of Clinical Development from April 2023 to May 2024. She is a clinician scientist with more than 15 years of research experience in academia and biotech.
Prior to joining Electra, Kim-Hien was Senior and Executive Medical Director of Clinical Development at Astex Pharmaceuticals from November 2019 to March 2023, where she worked on four drug programs for solid tumors and hematological malignancies.
She is an actively practicing hematologist in a volunteer capacity.
Kim-Hien received her D.O. and Ph.D. in Biochemistry and Molecular Biology from Michigan State University, and trained in hematology-medical oncology at the University of California, San Diego.
X
Chris Clark CFA
Chief Financial Officer
Chris has served as Chief Financial Officer of Electra Therapeutics since August 2026, and as our Executive Vice President, Strategy and Finance from December 2025 to August 2026. He brings more than two decades of life sciences investment experience, primarily in biotech. Throughout his career, he optimized capital allocation and investment strategies over multiple market cycles, with a particular focus on financing biopharma companies through participation in direct capital raises.
Previously, Chris was a Portfolio Manager, Equity Analyst – HealthCare at RS Investments, a Victory Capital investment franchise, from May 2007 to May 2025, where he led the firm’s investment in biopharma and life sciences across six separate fund strategies. His investment experience spanned public equities across all therapeutic areas, company stages, and market capitalizations. Earlier in his career, Chris was a Research Associate at TIAA-CREF, from 2004 to 2007, focusing on global pharmaceuticals, and a Research Assistant at Dresdner RCM.
Chris earned his B.A. in economics from the University of Virginia and is a Chartered Financial Analyst® (C.F.A.) Charterholder.
X
Gary S. Koe PhD
Chief Technical Officer
Gary has served as Chief Technical Officer at Electra Therapeutics since May 2025, previously serving as Senior Vice President, Head of Technical Operations from May 2024 to May 2025 and Vice President, Head of Technical Operations from November 2023 to May 2024. He brings over 30 years of biopharmaceutical development and large-scale biologics manufacturing experience.
Gary was also Vice President, Technical Operations at Star Therapeutics from March 2022 to November 2023, and served as Executive Director, Head of Operations at Star Therapeutics from November 2019 to March 2022. Prior to joining Electra Therapeutics, Gary served as Executive Director of Technical Operations at Aravive, Inc. from 2015 to 2019, working on the large-scale manufacture of a novel affinity Fc-sAXL fusion protein.
Gary earned his Ph.D. in Chemical Engineering from the University of California, Los Angeles, and a B.S. in Chemical Engineering from the University of California, Davis.
Nancy Stagliano PhD
Executive Chair
Nancy has served as Chairperson and a member of the board of directors of Electra Therapeutics since March 2019. She is CEO and chair of the Board of Neuron23, Inc., a South San Francisco–based precision neurology and immunology therapeutics company, serving as chair since October 2018 and as CEO since October 2020. Nancy has also served as chair of the board of directors of Star Therapeutics since June 2018. An experienced CEO, Nancy has led True North Therapeutics (acquired by Bioverativ in 2017), iPierian (acquired by BMS in 2014), and CytomX Therapeutics, a publicly held clinical-stage biopharmaceutical company, from 2008 to 2011. With more than 20 years of experience in the biotechnology industry, Nancy’s career path has always stayed close to the science.
Nancy has served as executive chair of Sundance Biosciences, Inc., a privately held biotechnology company, since January 2026. In the past, Nancy has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures.
Nancy has a Ph.D. in Neuroscience from the University of Miami School of Medicine and completed a postdoctoral fellowship at Harvard Medical School, as well an M.S. in Biomedical Engineering and a B.S. in Electrical Engineering, both from Drexel University.
X
Adam Rosenthal PhD
Director
Carl Gordon PhD, CFA
Director
Carl has served on the board of directors of Electra Therapeutics since March 2019. He is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, where he has served since January 1998. He currently serves on the boards of directors of Compass Therapeutics (since September 2015), BlossomHill Therapeutics (since February 2021), Scribe Therapeutics (since March 2021), and Lomond Therapeutics Holdings (since August 2024), and several other privately held companies.
Carl previously served on the boards of directors of Adicet Bio (August 2015 to April 2025), ArriVent Biopharma (December 2022 to June 2025), Gemini Therapeutics, which merged with Disc Medicine (April 2016 to December 2022), Keros Therapeutics (March 2020 to March 2026), Kinnate Biopharma (December 2019 to April 2024), MBX Biosciences (July 2020 to June 2025), ORIC Pharmaceuticals (November 2015 to November 2021), Terns Pharmaceuticals (October 2018 to February 2025), and Theseus Pharmaceuticals (June 2018 to February 2024).
Carl received a B.A. in Chemistry from Harvard College and a Ph.D. in molecular biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.
Matthew Fust MBA
Director
Matthew is a board member and advisor to life sciences companies. He serves on the boards of Nasdaq-listed Atara Biotherapeutics (since March 2014), Crinetics Pharmaceuticals (since March 2018), Neumora Therapeutics (since December 2020), and Ultragenyx Pharmaceutical (since January 2014), and on the boards of several venture-backed companies. He also consults with life sciences companies on corporate finance and strategy topics.
Previously, Matthew served as Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals from January 2009 through its acquisition by Amgen in October 2013, continuing as an employee of Amgen until January 2014. From May 2003 to December 2008, he served as Chief Financial Officer at Jazz Pharmaceuticals.
Matthew holds an undergraduate degree in Accounting from the University of Minnesota Duluth and an M.B.A. from the Stanford Graduate School of Business.
Beth Seidenberg MBA
Director
Beth has served on the board of directors of Electra Therapeutics since March 2019. Dr. Seidenberg is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients. From February 2002 to December 2004, Beth served as Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen. Prior to that, she was a senior executive in research and development at Bristol-Myers Squibb and at Merck & Co.
As the founding Managing Director of Westlake BioPartners, formed September 2018, general partner at Kleiner Perkins since May 2005, and numerous other endeavors, Seidenberg has incubated, and invested in, more than 40 biotech ventures since 2005. Among many others, they include ARMO Biosciences, Arresto Biosciences, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus Biosciences, iPierian, Kyverna Therapeutics, Livongo Health, Neuron23, Progyny, RAPT Therapeutics, Tesaro, Tmunity Therapeutics, and True North Therapeutics.
Beth’s impact has been recognized across the industry. She was awarded the 2022 Healthcare Businesswomen’s Association “Woman of the Year” Award and was recently named by Barron’s as one of the 100 most influential women in US finance. She was also recognized in the 2020 Forbes Midas List as a top tech investor.
In addition to her time in life science investing, Beth has significant senior-level industry experience, with leadership roles at Amgen, Bristol-Myers Squibb, and Merck Research Laboratories. Beth currently serves on the board of directors of Latigo Biotherapeutics (since July 2024), Vera Therapeutics (since June 2016), Kyverna Therapeutics (since September 2018), and Sagimet Biosciences (since April 2007), and several other privately held life sciences companies. She previously served on the board of directors of Acelyrin (October 2020 to May 2025), Atara Biotherapeutics (August 2012 to June 2023), and Progyny (May 2010 to November 2024).
Beth holds an M.D. from the University of Miami School of Medicine and a B.A. from Barnard College. She conducted her postgraduate training at The National Institutes of Health, George Washington University, and Johns Hopkins University School of Medicine.
X
Thomas Geninatti PhD
Director
Thomas has served as a member of the board of directors of Electra Therapeutics since October 2025 and is a Principal at Nextech Invest AG since October 2025, having served as a Senior Associate from September 2024 to October 2025, where he focuses on identifying and investing in innovative biotechnology companies developing transformative therapies in oncology and disease adjacencies. Thomas has also served as a member of the board of directors of Hexagon Bio, Inc., a privately held biotechnology company, since January 2025.
Before joining Nextech, Thomas served in numerous roles of increasing responsibility at Gilead Sciences from December 2019 to September 2024, most recently as Senior Director of Corporate Development, where he led Search and Evaluation for Oncology, driving strategic partnerships and investments to expand Gilead’s pipeline. Thomas took a brief hiatus from Gilead from May 2022 to September 2022 to serve as Senior Director, Business Development & Licensing, Oncology at Bayer.
Thomas started his career as a senior associate project manager and consultant at Deallus Consulting, where he supported global pharmaceutical companies on business development and corporate strategy initiatives.
Thomas holds a Ph.D. in Bioengineering from a joint program between the University of the Chinese Academy of Sciences and the Houston Methodist Research Institute, as well as B.S. and M.S. degrees in Biomedical Engineering from the Politecnico di Torino, Italy. He has also completed the Stanford LEAD Business Program.
Investors
Adam is the co-founder and former CEO of Electra Therapeutics. He is also the founder and current CEO of Star Therapeutics, the company that spun out Electra. He brings previous operating experience across multiple biotech companies focused on rare diseases, and broad expertise in company building, fundraising, business development, and strategic planning.
Previously, Adam served as Chief Business Officer at True North Therapeutics, where he raised more than $140M in private financings and contributed to the company’s acquisition by Bioverativ for $825M. His experience also includes serving as Vice President, Head of Corporate Development at iPierian, which was acquired by BMS for $725M, and being a Project Leader at the Boston Consulting Group.
Adam earned BS degrees in Electrical Engineering and Brain and Cognitive Science, and an MEng degree in Electrical Engineering and Computer Science, all at Massachusetts Institute of Technology, as well as a PhD in Biomedical Engineering at the Massachusetts Institute of Technology and Harvard.